1. Escudier B, Szczylik C, Eisen T, et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) [Abstract 4510]. J Clin Oncol. 2005; 23: 380s.
2. Ahmad T, Eisen T. Kinase inhibition with BAY 43‐9006 in renal cell carcinoma. Clin Cancer Res. 2004; 10(18 Suppl 2): 6388S–6392S.
3. Mendel DB, Laird D, Xin X, Louie SG, Christensen JG, Guangmin Li, Schreck RE, Abrama TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Li Sun, Cho Tang, Miller T, Shirazian S, McMahon G, Cherington JM. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacoki-netic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9(1): 327–337.
4. Lathia C, Lettieri J, Cihon F, Gallantine M, Radke M, Sundaresan P. Lack of effect of ketoconazole–mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006; 57 (5): 685–692. Epub Aug 25.
5. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY-43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19): 7099–7109.